Abstract
The drug-in-adhesive (DIA)-type matrix patches of lamotrigine are developed using variable permeation enhancers (oleic acid, PG, lemon oil and aloe vera), and drug in vitro release and its permeation are evaluated. Lamotrigine has been long used as an anti-epileptic, mood stabilizer, to treat bipolar disorder in adults and off label as an antidepressant. lamotrigine matrix patches comprising of Eudragit®RS100 (rate-controlling polymer) and DuroTak® 387-2510 (adhesive) were prepared by pouring the solution on backing membrane (3M-9720). The thickness of 120 µm was adjusted through micrometer film applicator. USP Apparatus V was used for the evaluation of release profile, which was fitted into various mathematical models. Quality characteristics of patches were determined through weight variation, moisture content, moisture uptake and drug content evaluation. FTIR studies were performed for drug-excipient compatibility; Franz diffusion cell was employed for studying in vitro permeation parameters such as flux, lag time, and ER. Skin sensitivity study of optimized patch was also performed. The release from patches comprising of PG and oleic acid was maximum, i.e., 96.24 ± 1.15% and 91.12 ± 1.11%, respectively. Formulations (A1–A5) exhibited Makoid–Banakar release profile. Formulation A3 consisting of oleic acid was optimized due to enhanced permeation of drug across skin compared to other enhancers with enhancement ratio of 3.55. Skin sensitivity study revealed patch as safe and non-allergenic. The study demonstrates that oleic acid can be used as a suitable permeation enhancer for transdermal delivery of lamotrigine from matrix-type patches.
Highlights
Transdermal drug delivery systems are suitable alternatives to conventional delivery routes and possess advantages of predicted and controlled rate of transport, avoiding firstpass effect and improved patient compliance (Prausnitz and Langer 2008)
The rate of delivery of much simpler and easy to fabricate matrix-type transdermal patches is usually controlled by skin permeation (Prausnitz et al 2004)
The current study focuses on developing a matrix-type transdermal patch of lamotrigine, a relatively new anti-epileptic agent which is not structurally related to compounds of this class but has pharmacological action similar to phenytoin (Leach et al 1986)
Summary
Transdermal drug delivery systems are suitable alternatives to conventional delivery routes and possess advantages of predicted and controlled rate of transport, avoiding firstpass effect and improved patient compliance (Prausnitz and Langer 2008). The rate of delivery of much simpler and easy to fabricate matrix-type transdermal patches is usually controlled by skin permeation (Prausnitz et al 2004). These systems comprise drug in the hydrophilic or lipophilic matrix (Valenta and Auner 2004). The current study focuses on developing a matrix-type transdermal patch of lamotrigine, a relatively new anti-epileptic agent which is not structurally related to compounds of this class but has pharmacological action similar to phenytoin (Leach et al 1986).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
